APEX1 and neutropenia: APE1 rs1130409 was associated with a decreased risk of grade 3-4 leukocytopenia (OR = 0.460; 95% CI: 0.241–0.879; p = 0.019) and grade 3-4 neutropenia (OR = 0.557; 95% CI: 0.321–0.967; p = 0.038) in dominant model (Zheng et al., 2017).